Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Cagrilintide and Semaglutide Combination Treatment Compared to a Weight-loss Inducing Diet on Energy Metabolism in Persons Living With Obesity: an Open-label Randomised Study

NCT07184086 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07184086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07184086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Cagrilintide and Semaglutide Combination Treatment Compared to a Weight-loss Inducing Diet on Energy Metabolism in Persons Living With Obesity: an Open-label Randomised Study
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 26, 2025
Completion date
February 9, 2028
Enrollment
80 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

obesity